Number： YB1-rt-PA（Modified version YB1 for thrombolysis）
Medicine： Recombinant urokinase（rt-PA）
Indication： Various thrombi
Shortcoming： RT-PA, a thrombolytic drug, has a short half-life of only 4-8 minutes, which can not alleviate the incidence of acute thrombosis.
Introduction： YB1 can be used not only in the field of tumor treatment, but also in the treatment of various thrombosis. YB1 RT PA is the first generation of targeted thrombolysis products. It is mainly characterized by carrying through YB1 and releasing urokinase at the thrombus site to achieve the effect of rapid targeted release of thrombolytic drugs. Urokinase is produced by the kidney in the human body and can directly activate plasminogen into plasmin. In medicine, urokinase is the first generation of natural thrombolytic drug extracted from urine.
Academic： According to China cardiovascular disease report 2019, cardiovascular disease is the leading cause of death in Chinese population. Worldwide, the number of deaths due to cardiovascular and cerebrovascular diseases such as cerebral thrombosis is about 12 million every year, which is close to a quarter of the total death toll. It is the number one killer of human health. The number of cardiovascular diseases is 330 million, including 13 million stroke, 11 million coronary heart disease, 5 million pulmonary heart disease, 8.9 million heart failure, 2.5 million rheumatic heart disease, 2 million congenital heart disease, 45.3 million lower extremity artery disease and 245 million hypertension. Thrombotic diseases, as one of the main forms of cardiovascular and cerebrovascular diseases, show high incidence rate, high recurrence rate, high disability rate and high mortality rate. Clinically, antiplatelet aggregation, anticoagulation and thrombolysis are the main methods for the treatment of stroke.
Data show that the scale of China's antithrombotic drug market maintains a steady and rapid growth trend. From 2014 to 2018, the market scale increased from 12.7 billion yuan to 20 billion yuan, with a compound growth rate of more than 12%.
The mechanism of urokinase rt-PA to dissolve thrombus
Green fluorescent signal: YB1 can quickly accumulate in the thrombus position and release thrombolytic enzyme
Schematic diagram of YB1 releasing rt-PA to dissolve thrombus